Success Stories: An Indian Manager of Quality Control in Pharmaceutical Drug Development Wins EB1-A Approval in Just 13 Days Due to Premium Processing Upgrade and Our Team’s Work

Case Summary:

North America Immigration Law Group specializes in representing clients from all over the country for I-140 immigration petitions. We specialize in employment-based immigration petitions and have a proven record of success. With over 32,000 successes we have first-hand knowledge of how USCIS adjudicates on I-140 cases.

So when we get clients who want to apply under any of the varied categories of EB1-A, NIW, EB-1-B, O1-A, etc. our team first makes sure to explain the process of adjudication to them and then do an initial background check of their academic and professional career thus far. So when a leading expert in the development of analytical bioassays for pharmaceuticals and biopharmaceuticals, including cell and gene therapy (CGT) products, in the field of pharmaceutical drug development, approached our firm, we took the initial steps and then having signed the retainer, began working on his petition. Our team was able to gather the following from the documents he furnished:

• He has achieved a consistent and notable record of success and influence in these areas of study and the field has recognized his authority by inviting him to review and evaluate the work of his peers no fewer than 21 times.
• His work has resulted in 5 peer-reviewed scientific articles and 1 book chapter and these publications have been cited 212 times by researchers in at least 27 countries according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of pharmaceutical drug development.
• Due to its clear implications for the development of cell-based bioassays and their applications in creating novel biopharmaceuticals, his research has already attracted the attention of the private sector.
• Not only has he shown that he meets at least three of the regulatory criteria, but the evidence in the aggregate also demonstrates his national and international acclaim and position at the very top of his field.
• Finally, we also collected 4 letters of recommendation from other experts which helped corroborate the information we had already provided.

Thus our team showed that his work on novel therapeutic product research has been essential and transformative in the field of pharmaceutical drug development and is thus of use to the United States. We were also able to prove that his work was indeed extraordinary too and thus should continue in the county. So when the approval came through after only 13 days, we were proud and happy to have worked on the case and we wish our client a very successful future.